Albuferon is a new protein created by fusing the gene for interferon alpha,
to the gene of albumin, producing a protein with properties of both interferon alpha and albumin.
Preclinical studies indicate that Albuferon should provide patients with a longer acting drug with
fewer side effects compared to recombinant human interferon alpha. Human Genome Sciences has begun
Phase I clinical trials, which are showing that it is well tolerated and has anti-viral effectiveness in Hep C patients (
